Industries > Pharma > Acromegaly Treatment Market Report to 2031

Back to Pharma Reports

Acromegaly Treatment Market Report to 2031

Forecasts By Disease Type (Ectopic Acromegaly and Pseudo Acromegaly), By Drug Class (Somatostatin Analogs (SSAs) (Somatuline Depot and Other SSAs), Dopamine Agonists (Bromocriptine Mesylate and Other Dopamine Agonists), and Growth Hormone Receptor Antagonist (Somavert)), By Route of Administration (Oral and Parenteral), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online pharmacies) PLUS COVID-19 Recovery Scenarios

PAGES: 373

PRODUCT CODE: PHA1084

SUBMARKET: Therapeutic Drugs

DOWNLOAD FREE SAMPLE

Licence

Clear

DOWNLOAD FREE SAMPLE

SKU: PHA1084 Categories: Pharma, Therapeutic Drugs Tag: PHA1084

Acromegaly Treatment Market– our new study reveals trends, R&D progress, and predicted revenues
Where is the Acromegaly Treatment market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead
Our 500+ page report provides 600+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Acromegaly Treatment Market. See how to exploit the opportunities.

Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets

Acromegaly Treatment Market: By Disease Type
• Ectopic Acromegaly
• Pseudo Acromegaly

Acromegaly Treatment Market: By Drug Class
• Somatostatin Analogs (SSAs)
• Somatuline Depot (Lanreotide)
• Others SSAs
• Dopamine Agonists (DAs)
• Bromocriptine Mesylate (Parlodel)
• Others DAs
• Growth Hormone Receptor Antagonist (GHRAs)
• Somavert (Pegvisomant)

Acromegaly Treatment Market: By Route of Administration
• Oral
• Parenteral

Acromegaly Treatment Market: By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:

• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa

The report also includes profiles and for some of the leading companies in the Acromegaly Treatment Market, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
Overall world revenue for Acromegaly Treatment Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Acromegaly Treatment Market report helps you
In summary, our 500+ page report provides you with the following knowledge:

• Revenue forecasts to 2031 for Acromegaly Treatment Market, with forecasts for Disease Type, Drug Class, Route of Administration, and Distribution Channel, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Acromegaly Treatment market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Acromegaly Treatment Market. Some of the company’s profiled in this report include Pfizer Inc., Novartis Pharma AG, GlaxoSmithKline plc, Midatech Pharma PLC, Strongbridge Biopharma plc, Chiasma Inc, Aegis Therapeutics LLC, Amryt Pharma plc, Antisense Therapeutics Ltd, Crinetics Pharmaceuticals Inc, Dauntless Pharmaceuticals Inc, and Ipsen Biopharmaceuticals Inc.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Acromegaly Treatment Market Report to 2031: Forecasts By Disease Type (Ectopic Acromegaly and Pseudo Acromegaly), By Drug Class (Somatostatin Analogs (SSAs) (Somatuline Depot and Other SSAs), Dopamine Agonists (Bromocriptine Mesylate and Other Dopamine Agonists), and Growth Hormone Receptor Antagonist (Somavert)), By Route of Administration (Oral and Parenteral), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online pharmacies) PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Acromegaly Treatment Market
2.1. Acromegaly Treatment Market Definition
2.2. Disease Type Submarkets Definitions
2.3. Drug Class Submarkets Definitions
2.4. Route of Administration Submarkets Definitions
2.5. Distribution Channel Submarkets Definitions
3. Acromegaly Treatment Market Overview
3.1. Global Acromegaly Treatment Market Size and Forecast by Region
3.2. Global Acromegaly Treatment Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of acromegaly
3.3.1.2. Ongoing clinical trials
3.3.2. Market Restraints/Challenges
3.3.2.1. High treatment cost
3.3.2.2. Lack of awareness among people
3.3.3. Opportunities
3.3.3.1. Increase in Government Initiatives
3.3.3.2. Rapid Technological advancements
3.3.3.3. Potential emerging market
3.3.4. Global Acromegaly Treatment Market: Trends
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.2. Weaknesses
3.3.5.3. Opportunities
3.3.5.4. Threats
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. The threat of New Entry
4. Global Acromegaly Treatment Market Analysis and Forecast 2021-2031, by Disease Type (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Ectopic Acromegaly
4.1.2. Pseudo Acromegaly
5. Global Acromegaly Treatment Market Analysis and Forecast, 2021-2031 by Drug Class (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Somatostatin Analogs (SSAs)
5.1.2. Somatuline Depot (Lanreotide)
5.1.3. Others SSAs
5.1.4. Dopamine Agonists (DAs)
5.1.5. Bromocriptine Mesylate (Parlodel)
5.1.6. Others DAs
5.1.7. Growth Hormone Receptor Antagonist (GHRAs)
5.1.8. Somavert (Pegvisomant)
6. Global Acromegaly Treatment Market Analysis and Forecast, 2021-2031 by Route of Administration (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Oral
6.1.2. Parenteral
7. Global Acromegaly Treatment Market Analysis and Forecast, 2021-2031 by Distribution Channel (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Hospital Pharmacies
7.1.2. Retail Pharmacies
7.1.3. Online Pharmacies
8. North America Acromegaly Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. North America Acromegaly Treatment Market Size and Forecast by Drug Class
8.3. North America Acromegaly Treatment Market Size and Forecast by Disease Type
8.4. North America Acromegaly Treatment Market Size and Forecast by Route of Administration
8.5. North America Acromegaly Treatment Market Size and Forecast by Distribution Channel
8.6. U.S. Acromegaly Treatment Market
8.7. Canada Acromegaly Treatment Market
9. Europe Acromegaly Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Europe Acromegaly Treatment Market Size and Forecast by Drug Class
9.3. Europe Acromegaly Treatment Market Size and Forecast by Disease Type
9.4. Europe Acromegaly Treatment Market Size and Forecast by Route of Administration
9.5. Europe Acromegaly Treatment Market Size and Forecast by Distribution Channel
9.6. UK Acromegaly Treatment Market
9.7. Germany Acromegaly Treatment Market
9.8. France Acromegaly Treatment Market
9.9. Rest of Europe Acromegaly Treatment Market
10. Asia Pacific Acromegaly Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Asia Pacific Acromegaly Treatment Market Size and Forecast by Drug Class
10.3. Asia Pacific Acromegaly Treatment Market Size and Forecast by Disease Type
10.4. Asia Pacific Acromegaly Treatment Market Size and Forecast by Distribution Channel
10.5. Asia Pacific Acromegaly Treatment Market Size and Forecast by Distribution Channel
10.6. China Acromegaly Treatment Market
10.7. India Acromegaly Treatment Market
10.8. Japan Acromegaly Treatment Market
10.9. Rest of Asia Pacific Acromegaly Treatment Market
11. Latin America Acromegaly Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Latin America Acromegaly Treatment Market Size and Forecast by Drug Class
11.3. Latin America Acromegaly Treatment Market Size and Forecast by Disease Type
11.4. Latin America Acromegaly Treatment Market Size and Forecast by Route of Administration
11.5. Latin America Acromegaly Treatment Market Size and Forecast by Distribution Channel
11.5.1. Brazil Acromegaly Treatment Market
11.5.2. Mexico Acromegaly Treatment Market
11.5.3. Rest of Latin America Acromegaly Treatment Market
12. MEA Acromegaly Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. MEA Acromegaly Treatment Market Size and Forecast by Drug Class
12.3. MEA Acromegaly Treatment Market Size and Forecast by Disease Type
12.4. MEA Acromegaly Treatment Market Size and Forecast by Route of Administration
12.5. MEA Acromegaly Treatment Market Size and Forecast by Distribution Channel
12.6. GCC Acromegaly Treatment Market
12.7. South Africa Acromegaly Treatment Market
12.8. Rest of MEA Acromegaly Treatment Market
13. Companies in the Acromegaly Treatment Market
13.1. Pfizer Inc.
13.1.1. Company Snapshot
13.1.2. Company Overview
13.1.3. Financial Performance (2015-2019)
13.1.3.1. Net Revenue
13.1.3.2. Gross Profit
13.1.3.3. Geographical Revenue, 2019
13.1.4. Product Offerings
13.1.5. Recent Initiatives (2017-2019)
13.2. Novartis Pharma AG
13.2.1. Company Snapshot
13.2.2. Company Overview
13.2.3. Financial Performance (2015-2019)
13.2.3.1. Net Revenue
13.2.3.2. Gross Profit
13.2.3.3. Geographical Revenue, 2019
13.2.4. Product Offerings
13.2.5. Recent Initiatives (2017-2019)
13.3. GlaxoSmithKline plc
13.3.1. Company Snapshot
13.3.2. Company Overview
13.3.3. Financial Performance (2015-2019)
13.3.3.1. Net Revenue
13.3.3.2. Gross Profit
13.3.3.3. Geographical Revenue, 2019
13.3.4. Product Offerings
13.3.5. Recent Initiatives (2017-2019)
13.4. Midatech Pharma PLC
13.4.1. Company Snapshot
13.4.2. Company Overview
13.4.3. Financial Performance (2015-2019)
13.4.3.1. Net Revenue
13.4.3.2. Gross Profit
13.4.3.3. Geographical Revenue, 2019
13.4.4. Product Offerings
13.4.5. Recent Initiatives (2017-2019)
13.5. Strongbridge Biopharma plc
13.5.1. Company Snapshot
13.5.2. Company Overview
13.5.3. Financial Performance (2015-2019)
13.5.3.1. Net Revenue
13.5.3.2. Gross Profit
13.5.3.3. Geographical Revenue, 2019
13.5.4. Product Offerings
13.5.5. Recent Initiatives (2017-2019)
13.6. Chiasma Inc.
13.6.1. Company Snapshot
13.6.2. Company Overview
13.6.3. Financial Performance (2015-2019)
13.6.3.1. Net Revenue
13.6.3.2. Gross Profit
13.6.3.3. Geographical Revenue, 2019
13.6.4. Product Offerings
13.6.5. Recent Initiatives (2017-2019)
13.7. Aegis Therapeutics LLC
13.7.1. Company Snapshot
13.7.2. Company Overview
13.7.3. Financial Performance (2015-2019)
13.7.3.1. Net Revenue
13.7.3.2. Gross Profit
13.7.3.3. Geographical Revenue, 2019
13.7.4. Product Offerings
13.7.5. Recent Initiatives (2017-2019)
13.8. Amryt Pharma plc
13.8.1. Company Snapshot
13.8.2. Company Overview
13.8.3. Financial Performance (2015-2019)
13.8.3.1. Net Revenue
13.8.3.2. Gross Profit
13.8.3.3. Geographical Revenue, 2019
13.8.4. Product Offerings
13.8.5. Recent Initiatives (2017-2019)
13.9. Antisense Therapeutics Ltd
13.9.1. Company Snapshot
13.9.2. Company Overview
13.9.3. Financial Performance (2015-2019)
13.9.3.1. Net Revenue
13.9.3.2. Gross Profit
13.9.3.3. Geographical Revenue, 2019
13.9.4. Product Offerings
13.9.5. Recent Initiatives (2017-2019)
13.10. Crinetics Pharmaceuticals Inc.
13.10.1. Company Snapshot
13.10.2. Company Overview
13.10.3. Financial Performance (2015-2019)
13.10.3.1. Net Revenue
13.10.3.2. Gross Profit
13.10.3.3. Geographical Revenue, 2019
13.10.4. Product Offerings
13.10.5. Recent Initiatives (2017-2019)
13.11. Other Notable Players
14. Conclusion
15. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

LIST OF TABLES
Table 1 Acromegaly Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2 Acromegaly Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3 Acromegaly Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4 Acromegaly Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAG R %) (COVID - Scenario W)
Table 5 Acromegaly Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6 Acromegaly Treatment Market Drivers & Restraints 2020
Table 7 Acromegaly Treatment Submarket Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8 Acromegaly Treatment Submarket Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9 Acromegaly Treatment Submarket Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10 Acromegaly Treatment Submarket Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11 Acromegaly Treatment Submarket Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12 Ectopic Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13 Ectopic Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14 Ectopic Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15 Ectopic Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16 Ectopic Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17 Pseudo Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18 Pseudo Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19 Pseudo Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20 Pseudo Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21 Pseudo Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22 Acromegaly Treatment Submarket Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 23 Acromegaly Treatment Submarket Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 24 Acromegaly Treatment Submarket Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 25 Acromegaly Treatment Submarket Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 26 Acromegaly Treatment Submarket Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 27 Somatostatin Analogs (SSAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28 Somatostatin Analogs (SSAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29 Somatostatin Analogs (SSAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30 Somatostatin Analogs (SSAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31 Somatostatin Analogs (SSAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32 Somatuline Depot (Lanreotide) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33 Somatuline Depot (Lanreotide) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34 Somatuline Depot (Lanreotide) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35 Somatuline Depot (Lanreotide) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36 Somatuline Depot (Lanreotide) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37 Others SSAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38 Others SSAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39 Others SSAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40 Others SSAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41 Others SSAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42 Dopamine Agonists (DAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43 Dopamine Agonists (DAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44 Dopamine Agonists (DAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45 Dopamine Agonists (DAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46 Dopamine Agonists (DAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47 Bromocriptine Mesylate (Parlodel) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48 Bromocriptine Mesylate (Parlodel) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49 Bromocriptine Mesylate (Parlodel) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50 Bromocriptine Mesylate (Parlodel) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51 Bromocriptine Mesylate (Parlodel) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52 Others DAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53 Others DAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54 Others DAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55 Others DAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56 Others DAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57 Growth Hormone Receptor Antagonist (GHRAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58 Growth Hormone Receptor Antagonist (GHRAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59 Growth Hormone Receptor Antagonist (GHRAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60 Growth Hormone Receptor Antagonist (GHRAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61 Growth Hormone Receptor Antagonist (GHRAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62 Somavert (Pegvisomant) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63 Somavert (Pegvisomant) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64 Somavert (Pegvisomant) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65 Somavert (Pegvisomant) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66 Somavert (Pegvisomant) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67 Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68 Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69 Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70 Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71 Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72 Oral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73 Oral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74 Oral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75 Oral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76 Oral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77 Parenteral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78 Parenteral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79 Parenteral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80 Parenteral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81 Parenteral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82 Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83 Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84 Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85 Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86 Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87 Hospital Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88 Hospital Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89 Hospital Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90 Hospital Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91 Hospital Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92 Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93 Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94 Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95 Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96 Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102 Regional Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103 Regional Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104 Regional Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105 Regional Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 106 Regional Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107 North America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108 North America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109 North America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110 North America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111 North America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112 North America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113 North America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114 North America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115 North America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116 North America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117 North America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118 North America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119 North America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120 North America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121 North America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122 North America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123 North America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124 North America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125 North America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126 North America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127 North America Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128 North America Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129 North America Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130 North America Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131 North America Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132 US Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133 US Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134 US Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135 US Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136 US Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137 Canada Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138 Canada Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139 Canada Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140 Canada Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141 Canada Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142 Europe Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143 Europe Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144 Europe Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145 Europe Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146 Europe Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147 Europe Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148 Europe Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149 Europe Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150 Europe Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151 Europe Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152 Europe Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153 Europe Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154 Europe Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155 Europe Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156 Europe Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157 Europe Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158 Europe Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159 Europe Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160 Europe Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161 Europe Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162 Europe Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163 Europe Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164 Europe Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165 Europe Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166 Europe Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167 UK Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168 UK Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169 UK Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170 UK Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171 UK Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172 Germany Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173 Germany Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174 Germany Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175 Germany Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176 Germany Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177 France Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178 France Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179 France Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180 France Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181 France Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182 Rest of Europe Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183 Rest of Europe Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184 Rest of Europe Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185 Rest of Europe Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186 Rest of Europe Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187 Asia Pacific Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188 Asia Pacific Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189 Asia Pacific Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190 Asia Pacific Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191 Asia Pacific Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192 Asia Pacific Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193 Asia Pacific Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194 Asia Pacific Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195 Asia Pacific Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196 Asia Pacific Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197 Asia Pacific Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198 Asia Pacific Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199 Asia Pacific Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200 Asia Pacific Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201 Asia Pacific Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202 Asia Pacific Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203 Asia Pacific Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204 Asia Pacific Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205 Asia Pacific Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206 Asia Pacific Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207 Asia Pacific Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208 Asia Pacific Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209 Asia Pacific Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210 Asia Pacific Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211 Asia Pacific Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212 China Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213 China Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214 China Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215 China Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216 China Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217 India Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218 India Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219 India Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220 India Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221 India Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222 Japan Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223 Japan Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224 Japan Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225 Japan Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226 Japan Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227 RoAPAC Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228 RoAPAC Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229 RoAPAC Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230 RoAPAC Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231 RoAPAC Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232 Middle East Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233 Middle East Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234 Middle East Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235 Middle East Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236 Middle East Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237 Middle East Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238 Middle East Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239 Middle East Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240 Middle East Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241 Middle East Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242 Middle East Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243 Middle East Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244 Middle East Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245 Middle East Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246 Middle East Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247 Middle East Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 248 Middle East Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 249 Middle East Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 250 Middle East Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 251 Middle East Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 252 Latin America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 253 Latin America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 254 Latin America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 255 Latin America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 256 Latin America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 257 Latin America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 258 Latin America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 259 Latin America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 260 Latin America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 261 Latin America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 262 Latin America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 263 Latin America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 264 Latin America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 265 Latin America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 266 Latin America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 267 Latin America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 268 Latin America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 269 Latin America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 270 Latin America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 271 Latin America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 272 Africa Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 273 Africa Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 274 Africa Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 275 Africa Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 276 Africa Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 277 Africa Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 278 Africa Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 279 Africa Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 280 Africa Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 281 Africa Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 282 Africa Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 283 Africa Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 284 Africa Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 285 Africa Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 286 Africa Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 287 Africa Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 288 Africa Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 289 Africa Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 290 Africa Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 291 Africa Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 292 Leading 10 Acromegaly Treatment Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 293 Pfizer Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 294 Pfizer Inc. Acromegaly Treatment Selected Recent Contracts 2019 (Date, Contract Type, Details)
Table 295 Pfizer Inc. Acromegaly Treatment Product Offering (Segment, Product Offerings)
Table 296 Novartis Pharma AG Profile 2019 (CEO, HQ, Founded, Website)
Table 297 Novartis Pharma AG Acromegaly Treatment Selected Recent Contracts 2019 (Date, Contract Type, Details)
Table 298 Novartis Pharma AG Acromegaly Treatment Product Offering (Segment, Product Offerings)
Table 299 GlaxoSmithKline plc Profile 2019 (CEO, HQ, Founded, Website)
Table 300 GlaxoSmithKline plc Acromegaly Treatment Selected Recent Contracts 2017-2019 (Date, Contract Type, Details)
Table 301 GlaxoSmithKline plc Acromegaly Treatment Product Offering (Segment, Product Offerings)
Table 302 Midatech Pharma PLC Profile 2019 (CEO, HQ, Founded, Website)
Table 303 Midatech Pharma PLC Acromegaly Treatment Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 304 Midatech Pharma PLC Acromegaly Treatment Product Offering (Segment, Product Offerings)
Table 305 Strongbridge Biopharma plc Profile 2019 (CEO, HQ, Founded, Website)
Table 306 Strongbridge Biopharma plc Acromegaly Treatment Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 307 Strongbridge Biopharma plccare Product Offering (Segment, Product Offerings)
Table 308 Chiasma Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 309 Chiasma Inc. Acromegaly Treatment Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 310 Chiasma Inc. Acromegaly Treatment Product Offering (Segment, Product Offerings)
Table 311 Aegis Therapeutics LLC Profile 2019 (CEO, HQ, Founded, Website)
Table 312 Aegis Therapeutics LLC Acromegaly Treatment Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 313 Aegis Therapeutics LLC Acromegaly Treatment Product Offering (Segment, Product Offerings)
Table 314 Amryt Pharma plc Profile 2019 (CEO, HQ, Founded, Website)
Table 315 Amryt Pharma plc Acromegaly Treatment Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 316 Amryt Pharma plc Acromegaly Treatment Product Offering (Segment, Product Offerings)
Table 317 Antisense Therapeutics Ltd Profile 2019 (CEO, HQ, Founded, Website)
Table 318 Antisense Therapeutics Ltd Acromegaly Treatment Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 319 Antisense Therapeutics Ltd Acromegaly Treatment Product Offering (Segment, Product Offerings)
Table 320 Crinetics Pharmaceuticals Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 321 Crinetics Pharmaceuticals Inc. Acromegaly Treatment Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 322 Crinetics Pharmaceuticals Inc. Acromegaly Treatment Product Offering (Segment, Product Offerings)
Table 323 Other Companies Involved in the Acromegaly Treatment Market 2020 (Company, Location)

LIST OF FIGURES
Figure 1 Acromegaly Treatment Market Overview by Disease Type
Figure 2 Acromegaly Treatment Market Overview by Drug Class
Figure 3 Acromegaly Treatment Market Overview by Route of Administration
Figure 4 Acromegaly Treatment Market Overview by Distribution Channel
Figure 5 Acromegaly Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 6 Acromegaly Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 7 Acromegaly Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 8 Acromegaly Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAG R %) (COVID - Scenario W)
Figure 9 Acromegaly Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 10 Acromegaly Treatment Market Drivers & Restraints 2020
Figure 11 Acromegaly Treatment Submarket Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 12 Acromegaly Treatment Submarket Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 13 Acromegaly Treatment Submarket Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 14 Acromegaly Treatment Submarket Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 15 Acromegaly Treatment Submarket Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 16 Ectopic Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 17 Ectopic Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 18 Ectopic Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 19 Ectopic Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 20 Ectopic Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 21 Pseudo Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 22 Pseudo Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 23 Pseudo Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 24 Pseudo Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 25 Pseudo Acromegaly Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 26 Acromegaly Treatment Submarket Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 27 Acromegaly Treatment Submarket Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 28 Acromegaly Treatment Submarket Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 29 Acromegaly Treatment Submarket Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 30 Acromegaly Treatment Submarket Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 31 Somatostatin Analogs (SSAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 32 Somatostatin Analogs (SSAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 33 Somatostatin Analogs (SSAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 34 Somatostatin Analogs (SSAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 35 Somatostatin Analogs (SSAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 36 Somatuline Depot (Lanreotide) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 37 Somatuline Depot (Lanreotide) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 38 Somatuline Depot (Lanreotide) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 39 Somatuline Depot (Lanreotide) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 40 Somatuline Depot (Lanreotide) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 41 Others SSAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 42 Others SSAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 43 Others SSAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 44 Others SSAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 45 Others SSAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 46 Dopamine Agonists (DAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 47 Dopamine Agonists (DAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 48 Dopamine Agonists (DAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 49 Dopamine Agonists (DAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 50 Dopamine Agonists (DAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 51 Bromocriptine Mesylate (Parlodel) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 52 Bromocriptine Mesylate (Parlodel) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 53 Bromocriptine Mesylate (Parlodel) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 54 Bromocriptine Mesylate (Parlodel) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 55 Bromocriptine Mesylate (Parlodel) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 56 Others DAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 57 Others DAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 58 Others DAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 59 Others DAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 60 Others DAs Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 61 Growth Hormone Receptor Antagonist (GHRAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 62 Growth Hormone Receptor Antagonist (GHRAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 63 Growth Hormone Receptor Antagonist (GHRAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 64 Growth Hormone Receptor Antagonist (GHRAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 65 Growth Hormone Receptor Antagonist (GHRAs) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 66 Somavert (Pegvisomant) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 67 Somavert (Pegvisomant) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 68 Somavert (Pegvisomant) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 69 Somavert (Pegvisomant) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 70 Somavert (Pegvisomant) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 71 Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 72 Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 73 Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 74 Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 75 Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 76 Oral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 77 Oral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 78 Oral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 79 Oral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 80 Oral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 81 Parenteral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 82 Parenteral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 83 Parenteral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 84 Parenteral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 85 Parenteral Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 86 Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 87 Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 88 Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 89 Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 90 Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 91 Hospital Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 92 Hospital Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 93 Hospital Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 94 Hospital Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 95 Hospital Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 96 Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 97 Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 98 Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 99 Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 100 Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 101 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 102 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 103 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 104 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 105 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 106 Regional Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 107 Regional Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 108 Regional Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 109 Regional Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 110 Regional Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 111 North America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 112 North America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 113 North America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 114 North America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 115 North America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 116 North America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 117 North America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 118 North America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 119 North America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 120 North America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 121 North America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 122 North America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 123 North America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 124 North America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 125 North America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 126 North America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 127 North America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 128 North America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 129 North America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 130 North America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 131 North America Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 132 North America Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 133 North America Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 134 North America Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 135 North America Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 136 US Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 137 US Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 138 US Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 139 US Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 140 US Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 141 Canada Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 142 Canada Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 143 Canada Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 144 Canada Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 145 Canada Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 146 Europe Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 147 Europe Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 148 Europe Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 149 Europe Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 150 Europe Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 151 Europe Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 152 Europe Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 153 Europe Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 154 Europe Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 155 Europe Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 156 Europe Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 157 Europe Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 158 Europe Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 159 Europe Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 160 Europe Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 161 Europe Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 162 Europe Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 163 Europe Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 164 Europe Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 165 Europe Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 166 Europe Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 167 Europe Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 168 Europe Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 169 Europe Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 170 Europe Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 171 UK Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 172 UK Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 173 UK Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 174 UK Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 175 UK Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 176 Germany Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 177 Germany Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 178 Germany Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 179 Germany Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 180 Germany Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 181 France Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 182 France Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 183 France Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 184 France Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 185 France Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 186 Rest of Europe Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 187 Rest of Europe Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 188 Rest of Europe Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 189 Rest of Europe Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 190 Rest of Europe Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 191 Asia Pacific Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 192 Asia Pacific Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 193 Asia Pacific Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 194 Asia Pacific Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 195 Asia Pacific Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 196 Asia Pacific Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 197 Asia Pacific Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 198 Asia Pacific Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 199 Asia Pacific Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 200 Asia Pacific Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 201 Asia Pacific Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 202 Asia Pacific Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 203 Asia Pacific Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 204 Asia Pacific Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 205 Asia Pacific Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 206 Asia Pacific Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 207 Asia Pacific Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 208 Asia Pacific Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 209 Asia Pacific Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 210 Asia Pacific Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 211 Asia Pacific Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 212 Asia Pacific Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 213 Asia Pacific Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 214 Asia Pacific Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 215 Asia Pacific Acromegaly Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 216 China Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 217 China Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 218 China Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 219 China Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 220 China Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 221 India Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 222 India Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 223 India Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 224 India Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 225 India Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 226 Japan Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 227 Japan Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 228 Japan Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 229 Japan Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 230 Japan Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 231 RoAPAC Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 232 RoAPAC Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233 RoAPAC Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234 RoAPAC Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235 RoAPAC Acromegaly Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236 Middle East Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237 Middle East Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238 Middle East Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239 Middle East Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240 Middle East Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241 Middle East Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242 Middle East Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243 Middle East Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244 Middle East Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245 Middle East Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246 Middle East Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 247 Middle East Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248 Middle East Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249 Middle East Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250 Middle East Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251 Middle East Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252 Middle East Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253 Middle East Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254 Middle East Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255 Middle East Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256 Latin America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257 Latin America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258 Latin America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259 Latin America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260 Latin America Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261 Latin America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262 Latin America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263 Latin America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264 Latin America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265 Latin America Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266 Latin America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267 Latin America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268 Latin America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269 Latin America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270 Latin America Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271 Latin America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272 Latin America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273 Latin America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274 Latin America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275 Latin America Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276 Africa Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277 Africa Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278 Africa Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279 Africa Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280 Africa Acromegaly Treatment Market Forecast by Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281 Africa Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282 Africa Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283 Africa Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284 Africa Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285 Africa Acromegaly Treatment Market Forecast by Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286 Africa Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287 Africa Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288 Africa Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289 Africa Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290 Africa Acromegaly Treatment Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291 Africa Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292 Africa Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293 Africa Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294 Africa Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295 Africa Acromegaly Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)

Companies Profiled in the Report
1. Pfizer Inc.
2. Novartis Pharma AG
3. GlaxoSmithKline plc
4. Midatech Pharma PLC
5. Strongbridge Biopharma plc
6. Chiasma Inc.
7. Aegis Therapeutics LLC
8. Amryt Pharma plc
9. Antisense Therapeutics Ltd
10. Crinetics Pharmaceuticals Inc.
11. Dauntless Pharmaceuticals Inc.
12. Ipsen Biopharmaceuticals Inc.

List of Companies Mentioned in the Report:
1. Johnson & Johnson
2. Roche
3. Novartis
4. Sanofi
5. Bayer
6. Merck & Co. (MSD)
7. Eli Lilly
8. Astrazeneca
9. Teva
10. CR Pharmaceutical
11. Bristol-Myers Squibb
12. Merck (KGaA)
13. Novo Nordisk
14. Takeda
15. Allergan
16. Astellas Pharma
17. Mylan
18. Otsuka
19. Daiichi Sankyo
20. Valeant Pharmaceuticals
21. UCB
22. Zoetis
23. Eisai
24. Chugai Pharmaceutical
25. Perrigo
26. Sun Pharmaceutical
27. Mitsubishi Tanabe Pharma
28. Sichuan Languang Development
29. Sumitomo Dainippon Pharma
30. Yunnan Baiyao
31. Aspen Pharmacare
32. Endo
33. Kangmei Pharmaceutical
34. Galenica
35. Guangzhou Baiyunshan Pharmaceutical
36. Kyowa Hakko Kirin
37. Mallinckrodt
38. Shionogi & Co.
39. Shanghai Fosun Pharmaceutical
40. Stada Arzneimittel
41. Lundbeck
42. Zhejiang International
43. Lupin
44. Taisho Pharmaceutical
45. Tasly Pharmaceutical
46. Ipsen
47. Sino Biopharmaceutical
48. Ono Pharmaceutical
49. Aurobindo
50. Cipla

List of Organizations Mentioned in the Report:
1. European Commission
2. European Medicines Agency
3. Food and Drug Administration
4. Medicines and Healthcare Regulatory Agency
5. Ministry of Industry and Information technology
6. National Institute of Health
7. World Health Organisation (WHO)
8. Centers for Disease Control and Prevention
9. National Academy of Medicine
10. Agency for Healthcare Research and Quality
11. National Accreditation Board for Hospitals & Healthcare Providers
12. National Institute for Health Research
13. Chinese Food and Drug Administration
14. Care Quality Commission
15. British Medical Association
16. United States Department of Health and Human Services
17. Healthcare Information and Management Systems Society
18. Patient safety organization
19. NHS Digital
20. Australian Commission On Safety And Quality In Health Care

Download sample pages

Complete the form below to download your free sample pages for Acromegaly Treatment Market Report to 2031

Download sample pages

Complete the form below to download your free sample pages for Acromegaly Treatment Market Report to 2031

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

READ

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

READ

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

READ

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

READ

Industries > Pharma > Acromegaly Treatment Market Report to 2031

Back to Pharma Reports

Acromegaly Treatment Market Report to 2031

Download sample pages

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

Our Clients